گوگل و شرکت مشهور نوارتیس که در حوزه تولید و فروش دارو رتبه دوم دنیا را در اختیار دارد، امروز طی قراردادی خبر از همکاری یکدیگر برای توسعه طرح لنزهای چشمی گوگل دادند. این لنز ویژه در ماه ژانویه توسط بخش گوگل ایکس معرفی شده بود.
این لنزهای هوشمند با استفاده از سنسورهای غیرتهاجمی آنالیز آب چشم بیمار را بر عهده میگیرند و از این طریق اطلاعات قند خون بیماران دیابتی به شکل مداوم ثبت میشود. این اطلاعات سپس به موبایل بیمار ارسال شده تا وی برآورد دقیقی از بیماری و افت و خیز آن داشته باشد.
نوارتیس حالا لایسنس این محصول را دریافت کرده و بخش چشم این شرکت با نام Alcon با توسعه آن مقدمات تجاریسازی این لنزها را دنبال خواهد کرد.
نکته قابل توجهی که در اطلاعیه نوارتیس دیده میشود، اشاره این شرکت به کاربردهای بیشتری غیر از کنترل قند خون بیماران دیابتی برای محصول گوگل میباشد. کاربردهای پیشرفتهای چون «بازگرداندن اتوفوکوس طبیعی چشم» و دیگر برنامهها که با تعبیه مستقیم آن در چشم بیمار میسر خواهد شد.
در گذشته هنگامی که از طرحهای بخش سری گوگل به نام گوگل ایکس یاد میشد، عده زیادی از کارشناسان تجاریسازی موفقی را برای آن متصور نبودند. حالا دو محصول بزرگ این بخش یعنی خودروهای بدون راننده و لنزهای کنترل گلوکز به چنین فرآیندی نزدیک شدهاند و محصول مشهور دیگر آن گوگل گلس نیز مدتی طولانی است که وارد بازار شده است.
منبع : novartis
Agreement is a first step for Novartis to evolve technology to manage human diseases and conditions
The digital press release with multimedia content can be accessed here:
Basel, Switzerland, July 15, 2014 – Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its “smart lens” technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google’s “smart lens” technology with the potential to transform eye care and further enhance Alcon’s pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals.
The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google’s key advances in the miniaturization of electronics complement Novartis’s deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
“We are looking forward to working with Google to bring together their advanced technology and our extensive knowledge of biology to meet unmet medical needs,” said Novartis CEO Joseph Jimenez. “This is a key step for us to go beyond the confines of traditional disease management, starting with the eye.”
“Our dream is to use the latest technology in the miniaturization of electronics to help improve the quality of life for millions of people,” said Sergey Brin, Co-Founder, Google. “We are very excited to work with Novartis to make this dream come true.”
Under the agreement, Google[x] and Alcon will collaborate to develop a “smart lens” that has the potential to address ocular conditions. The smart lens technology involves non-invasive sensors, microchips and other miniaturized electronics which are embedded within contact lenses. Novartis’ interest in this technology is currently focused in two areas:
Helping diabetic patients manage their disease by providing a continuous, minimally invasive measurement of the body’s glucose levels via a “smart contact lens” which is designed to measure tear fluid in the eye and connects wirelessly with a mobile device;
For people living with presbyopia who can no longer read without glasses, the “smart lens” has the potential to provide accommodative vision correction to help restore the eye’s natural autofocus on near objects in the form of an accommodative contact lens or intraocular lens as part of the refractive cataract treatment.
The agreement marries Google’s expertise in miniaturized electronics, low power chip design and microfabrication with Alcon’s expertise in physiology and visual performance of the eye, clinical development and evaluation, as well as commercialization of contact and intraocular lenses. Through the collaboration, Alcon seeks to accelerate product innovation based on Google’s “smart lens” technology.
“Alcon and Google have a deep and common passion for innovation,” said Jeff George, Division Head of Alcon. “By combining Alcon’s leadership in eye care and expertise in contact lenses and intraocular lenses with Google’s innovative “smart lens” technology and groundbreaking speed in research, we aim to unlock a new frontier to jointly address the unmet medical needs of millions of eye care patients around the world.”
The foregoing release contains forward-looking statements that can be identified by words such as “potential,” “opportunity,” “pipeline,” “subject to anti-trust approvals,” “aims,” “looking forward to,” “will,” “seeks,” “could,” or similar terms, or by express or implied discussions regarding the potential future development of products based on the Google “smart lens” technology, potential additional collaborations between Google and Novartis Group companies, or regarding potential future revenues from such projects. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that products based on the Google “smart lens” technology or any other products based on collaborations between Google and Novartis Group companies will be successfully developed, or approved for sale in any market, or at any particular time. Nor can there be any guarantee that any such products will be commercially successful in the future. In particular, management’s expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally, including an unexpected failure to obtain necessary government approvals for the collaboration, or unexpected delays in obtaining such approvals; the uncertainties inherent in research and development, including unexpected research failures or delays, unexpected collaboration issues, and unexpected clinical trial results; the company’s ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.